OptimizeRx 경영진
경영진 기준 점검 3/4
OptimizeRx CEO는 Steve Silvestro, Jan2025 에 임명되었습니다 의 임기는 1.33 년입니다. 총 연간 보상은 $2.72M, 18.4% 급여 및 81.6% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $722.90K 가치에 해당하는 회사 주식의 0.6% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.1 년과 8.2 년입니다.
핵심 정보
Steve Silvestro
최고경영자
US$2.7m
총 보수
| CEO 급여 비율 | 18.40% |
| CEO 재임 기간 | 1.3yrs |
| CEO 지분 보유율 | 0.6% |
| 경영진 평균 재임 기간 | 3.1yrs |
| 이사회 평균 재임 기간 | 8.2yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 01
OPRX: Share Repurchases And Margin Gains Will Support Future Upside Potential
The analyst price target for OptimizeRx has moved from $32 to $20 as analysts factor in softer 2026 revenue expectations, lower revenue growth assumptions, falling peer multiples, and a higher discount rate, partly offset by improved profit margin forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Recent research updates show that while price targets on OptimizeRx have been reset lower, several bullish analysts still highlight positive angles around execution, profitability, and capital allocation.
내러티브 업데이트 • Apr 17
OPRX: Profit Execution And US$10m Buybacks Will Support Future Upside
Analysts have trimmed the blended price target for OptimizeRx to $14.50, reflecting softer 2026 revenue expectations, reduced revenue visibility, and lower peer multiples, partially offset by improved profit forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Street research on OptimizeRx has turned more cautious on the revenue outlook through 2026, but there is still a split between what bullish analysts focus on and what more bearish analysts are worried about.내러티브 업데이트 • Apr 02
OPRX: Profit Focus And Buybacks Will Support Future Share Upside
Analysts have lowered their average price targets for OptimizeRx into the low to mid teens in dollar terms, citing reduced 2026 revenue visibility, softer pharma marketing budgets, pressure from peer multiples, and a greater focus on profitability and share repurchases. Analyst Commentary Street research on OptimizeRx has converged around lower price targets but with different degrees of optimism on execution, growth prospects, and valuation.내러티브 업데이트 • Mar 19
OPRX: Margin Discipline And Buybacks Will Support Future Upside Potential
Analysts have reduced the fair value estimate for OptimizeRx from $24.33 to $14.50, citing lower revenue growth expectations, reduced revenue visibility into 2026, and lower peer P/E multiples. These factors are partly offset by firmer profit margin forecasts and buy ratings that remain in place across several firms.내러티브 업데이트 • Mar 05
OPRX: Expanded Point Of Care Network Will Support Further Upside
Analysts have fine tuned their OptimizeRx price target to $24.33. This reflects updated assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiple.
내러티브 업데이트 • Feb 19
OPRX: New Data Partnerships Will Support Long Term Earnings Power
Analysts now maintain their price target for OptimizeRx at $17.00, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E that they view as broadly offsetting each other. What's in the News Announced a data collaboration with Experian at CES 2026 to connect OptimizeRx Micro-Neighborhood audiences with Experian's identity graph for onboarding, curation, and measurement of consumer audiences at scale (Client Announcements).내러티브 업데이트 • Feb 05
OPRX: Q3 Outperformance And 2026 Guidance Will Strengthen Long Term Earnings Power
Analysts have lifted their average price targets on OptimizeRx into a US$21 to US$32 range, citing stronger than guided Q3 performance, improved visibility after 2024, and expectations for ongoing double digit growth with expanding margins. Analyst Commentary Street research after the Q3 report has centered on stronger than guided results and higher price targets, with analysts highlighting improved earnings and better visibility beyond 2024.내러티브 업데이트 • Jan 21
OPRX: Q3 Execution Rebound And 2026 Guidance Will Support Further Upside
Analysts have lifted their blended price targets on OptimizeRx to a range of US$21 to US$32, citing stronger than guided Q3 revenue and EPS, improved visibility after 2024 execution issues, and continuing momentum that supports expectations for double digit growth with expanding margins. Analyst Commentary Across the Street, bullish analysts are taking Q3 as a sign that OptimizeRx may be getting back on track after earlier execution issues, and they have shifted their valuation ranges higher as a result.내러티브 업데이트 • Jan 07
OPRX: Higher Guidance And Margin Expansion Will Reshape Long Term Earnings Power
Analysts have lifted their fair value estimate for OptimizeRx from US$11.00 to US$17.00, reflecting higher price targets supported by recent revenue and EPS outperformance, improved growth visibility, and expectations for margin expansion. Analyst Commentary Street research on OptimizeRx has been broadly positive around the latest quarter, with several firms raising their price targets after revenue and EPS outperformance and clearer guidance.내러티브 업데이트 • Dec 24
OPRX Will Extend Double Digit Revenue Trajectory With New Multi Year Partnerships
Analysts have lifted their price target on OptimizeRx by $5 to $32 per share, citing consistently strong quarterly outperformance, improving visibility after last year's weak execution, and a more durable outlook for double digit revenue growth and expanding margins. Analyst Commentary Bullish analysts are increasingly aligned around a constructive view of OptimizeRx, pointing to a series of price target hikes following its latest quarterly results.내러티브 업데이트 • Dec 09
OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside
Analysts have nudged their price targets on OptimizeRx higher, with recent increases across the Street ranging from about $1 to $10 per share to reflect stronger than expected Q3 revenue and EPS, improved visibility, and confidence in sustained double digit growth and margin expansion. Analyst Commentary Bullish analysts highlighted that the latest quarter materially exceeded revenue expectations, driving meaningful EPS upside and reinforcing confidence in a durable, double digit growth profile.내러티브 업데이트 • Nov 25
OPRX: Multi-Year Guidance and Recurring Revenue Will Drive Upside Momentum
OptimizeRx's analyst price target has increased from $22 to approximately $24.33 per share. This reflects ongoing revenue outperformance and improved visibility that analysts attribute to strong quarterly results and the company's growing momentum.분석 기사 • Nov 23
OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk
OptimizeRx Corporation ( NASDAQ:OPRX ) shareholders won't be pleased to see that the share price has had a very rough...내러티브 업데이트 • Nov 08
OPRX: Expanding Margins and Subscription Model Will Drive Shareholder Value Forward
OptimizeRx's analyst fair value target has been raised from $19 to $22.00 per share. This change reflects stronger quarterly results, improved growth prospects, and expanding profit margins, according to analysts.분석 기사 • Oct 07
Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Aug 27
Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?
Key Insights OptimizeRx's estimated fair value is US$28.97 based on 2 Stage Free Cash Flow to Equity OptimizeRx's...내러티브 업데이트 • Aug 15
Pharmaceutical Digital Engagement Will Unlock Future Value
Despite near-term cautious revenue guidance, analysts remain optimistic on OptimizeRx due to Q2 earnings outperformance, improved management transparency, and ongoing strategic initiatives, maintaining the consensus price target at $19.00. Analyst Commentary Bullish analysts highlight OptimizeRx’s Q2 revenues and adjusted EBITDA significantly surpassing forecasts.분석 기사 • May 09
Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
OptimizeRx Corporation ( NASDAQ:OPRX ) shares have continued their recent momentum with a 33% gain in the last month...
새 내러티브 • Apr 08
A Subscription Model And EHR Network Will Reshape Healthcare
Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.분석 기사 • Apr 06
Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, OptimizeRx fair value estimate is US$6.02 Current share price...분석 기사 • Mar 08
We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Feb 14
At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?
OptimizeRx Corporation ( NASDAQ:OPRX ), is not the largest company out there, but it received a lot of attention from a...분석 기사 • Dec 15
Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost
OptimizeRx Corporation ( NASDAQ:OPRX ) shareholders are no doubt pleased to see that the share price has bounced 30% in...분석 기사 • Nov 16
Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Jul 30
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Jan 09
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
OptimizeRx Corporation ( NASDAQ:OPRX ) shares have continued their recent momentum with a 36% gain in the last month...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Dec 31 2025 | US$3m | US$500k | US$5m |
| Sep 30 2025 | n/a | n/a | US$34k |
| Jun 30 2025 | n/a | n/a | -US$10m |
| Mar 31 2025 | n/a | n/a | -US$15m |
| Dec 31 2024 | US$973k | US$400k | -US$20m |
| Sep 30 2024 | n/a | n/a | -US$24m |
| Jun 30 2024 | n/a | n/a | -US$18m |
| Mar 31 2024 | n/a | n/a | -US$18m |
| Dec 31 2023 | US$970k | US$385k | -US$18m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$14m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$2m | US$330k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$7m |
| Mar 31 2022 | n/a | n/a | -US$3m |
| Dec 31 2021 | US$1m | US$330k | US$378k |
| Sep 30 2021 | n/a | n/a | US$1m |
| Jun 30 2021 | n/a | n/a | US$789k |
| Mar 31 2021 | n/a | n/a | -US$641k |
| Dec 31 2020 | US$866k | US$300k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$6m |
| Jun 30 2020 | n/a | n/a | -US$7m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$1m | US$189k | -US$3m |
보상 대 시장: Steve의 총 보수(USD2.72M)는 US 시장에서 비슷한 규모 기업의 평균(USD621.92K)보다 높습니다.
보상과 수익: Steve의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Steve Silvestro (47 yo)
1.3yrs
재임 기간
US$2,717,717
보수
Mr. Stephen L. Silvestro, also known as Steve, has been the Chief Executive Officer of OptimizeRx Corporation since January 2025 and its Director since June 2025. He served as President at OptimizeRx Corp....
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$2.72m | 0.60% $ 722.9k | |
| Chief Financial & Strategic Officer | 4.6yrs | US$1.52m | 0.39% $ 471.4k | |
| Chief Commercial Officer | 2.6yrs | US$1.54m | 0.18% $ 223.4k | |
| Chief Operating Officer | less than a year | 데이터 없음 | 0.053% $ 64.4k | |
| Chief Legal & Administrative Officer | 5.3yrs | US$2.51m | 0.26% $ 315.1k | |
| Media Relations Manager | no data | 데이터 없음 | 데이터 없음 | |
| Chief Business Officer | less than a year | 데이터 없음 | 0.11% $ 137.1k | |
| Chief Product Officer & CTO | 3.6yrs | 데이터 없음 | 0.13% $ 153.0k | |
| Controller | 7.6yrs | 데이터 없음 | 데이터 없음 | |
| Human Resources Manager | no data | 데이터 없음 | 데이터 없음 |
3.1yrs
평균 재임 기간
47yo
평균 나이
경험이 풍부한 관리: OPRX의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.1 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Independent Director | 8.2yrs | US$234.99k | 0.18% $ 222.2k | |
| Independent Director | 2.3yrs | US$227.99k | 0.063% $ 76.0k | |
| Independent Director | 5.8yrs | US$200.99k | 0.25% $ 306.1k | |
| Independent Chairperson of the Board | 10.7yrs | US$268.99k | 0.33% $ 406.2k | |
| Head of Medical Advisory Board | 8.2yrs | US$112.91k | 데이터 없음 | |
| Independent Director | 9.3yrs | US$203.99k | 2.08% $ 2.5m | |
| Independent Director | less than a year | 데이터 없음 | 데이터 없음 |
8.2yrs
평균 재임 기간
67yo
평균 나이
경험이 풍부한 이사회: OPRX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 8.2 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/07 14:59 |
| 종가 | 2026/05/07 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
OptimizeRx Corporation는 12명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Constantine Davides | Citizens JMP Securities, LLC |
| Eric Martinuzzi | Lake Street Capital Markets, LLC |